As testing for COVID-19 in the U.S. (or lack thereof) has been a much-discussed topic over the past month, shares of one diagnostics and pharmaceutical company with the potential to help test for the disease have been all over the place. However, as today’s article outlines, “On April 6, there was a new report of [this company] partnering with hospitals around the country for COVID-19 testing and maintain their 24-hour turnaround time. They have now tested almost 200,000 patients at a pace of 20,000 to 35,000 tests a day” – and the company’s CEO has been buying up shares on this development that could send its share price higher. For more, CLICK HERE.